enVVeno MedicalNVNO
NVNO
About: enVVeno Medical Corp is a medical device company focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
Employees: 31
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
528% more call options, than puts
Call options by funds: $289K | Put options by funds: $46K
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
3% less funds holding
Funds holding: 36 [Q3] → 35 (-1) [Q4]
14.78% less ownership
Funds ownership: 39.09% [Q3] → 24.31% (-14.78%) [Q4]
26% less capital invested
Capital invested by funds: $17.5M [Q3] → $12.9M (-$4.62M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for NVNO.
Financial journalist opinion
Based on 3 articles about NVNO published over the past 30 days
Neutral
Accesswire
3 days ago
enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
On-demand video webcast now available here IRVINE, CA / ACCESS Newswire / February 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it participated in the Virtual Investor "Top 5 for ‘25" On-Demand Conference . As part of the event, Robert Berman, Chief Executive Officer of enVVeno, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to the Company in 2025.
Neutral
Accesswire
3 days ago
One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum
One-year follow-up data demonstrates sustained improvements across venous specific quality-of-life (QoL) indicators. PMA application for the VenoValve submitted in November 2024, with an FDA decision expected in the second half of 2025.
Neutral
Accesswire
2 weeks ago
Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting
Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months. 78% of subjects maintained a clinically meaningful benefit of more than 3 points in rVCSS at 24 months, with an average improvement of 8.2 points among the responder cohort.
Neutral
Accesswire
2 months ago
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe
Successful Completion of All Planned Implants in GLP Study enVVe Delivery System Demonstrates Consistent Performance Company Maintains Timeline for IDE Application Submission by Mid-2025, Pending GLP Study Results IRVINE, CA / ACCESSWIRE / December 16, 2024 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the successful completion of the final wave of implants for shorter-term subjects in its six-month pre-clinical GLP study for enVVe, its transcatheter-delivered replacement venous valve. The successful completion of all planned implants in the GLP study, including both long-term and short-term subjects, completes a critical phase of the study.
Neutral
Accesswire
2 months ago
enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website
Interviews with participating patients from the VenoValve® U.S. Pivotal Trial Webcast replay from with the presenting Primary Investigators Presentation with data from the VenoValve U.S. Pivotal Trial Access the Recap Website Here! IRVINE, CA / ACCESSWIRE / November 27, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the launch of a recap website which highlights the Company's participation at the recently held 51st Annual Vascular and Endovascular, Techniques and Horizons (VEITH) Symposium.
Positive
Zacks Investment Research
2 months ago
NVNO Completes Application for VenoValve's PMA, Shares Likely to Gain
The FDA's approval of VenoValve's PMA has the potential to significantly expand NVNO's portfolio of bioprosthetic solutions.
Neutral
Accesswire
3 months ago
enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium
85% Clinical Meaningful Benefit Responder Rate 7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort 75% Median Reduction in Pain (VAS) 87% Median Ulcer Area Reduction 97% Target Vein Patency Rate Improvement in All Patient Reported Quality-of-Life Indicators Company to Host Video Conference Call with VEITH Presenters Today at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 20, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, will present one year data on all subjects from the VenoValve U.S. pivotal trial today at the 51st Annual Vascular and Endovascular, Techniques and Horizons (VEITH) Symposium in New York City. The definitive one-year data supports the application submitted earlier this week by enVVeno Medical seeking pre-market authorization (PMA) from the U.S. Food and Drug Administration (FDA) to market and sell the VenoValve in the U.S. Among the data being presented at VEITH are: Eighty five percent (85%) of the subjects in the VenoValve pivotal study that reached the one-year milestone achieved a clinically meaningful benefit of a three (3) or more point improvement in revised Venous Clinical Severity Score (rVCSS).
Neutral
Accesswire
3 months ago
enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval
Definitive One Year Data from PMA Application to be Presented Wednesday at 51st Annual VEITH Symposium Company to Host a Conference Call with the PIs Presenting the Pivotal Trial Data on Wednesday, November 20th at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 19, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it has submitted its application with the U.S. Food and Drug Administration (FDA) seeking approval to market and sell the VenoValve in the United States. Four (4) out of five (5) modules that comprise the VenoValve PMA application have been submitted, reviewed and approved by the FDA.
Charts implemented using Lightweight Charts™